69 results about "Coronavirus vaccination" patented technology

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

An mRNA vaccine encapsulated with lipid nanoparticles for PDCoV, a preparation method and an application thereof are provided, and the mRNA vaccine for PDCoV includes at least one of sequences as described in SEQ ID NO: 1-2; the lipid nanoparticle-encapsulated mRNA vaccines includes the mRNA vaccine, and lipids for encapsulating the mRNA vaccine, and the lipids are formed by mixing ionizable liposome, distearoyl phosphatidylcholine, cholesterol and PEG liposome.

Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and / or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and / or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

Provided herein are adenoviral vectors encoding spike protein variants of an SARS-CoV2 coronavirus, and compositions comprising the vectors. Also provided are methods of preventing and treating SARS-CoV2 using the provided compositions.

The invention discloses an avian coronavirus mRNA (messenger Ribonucleic Acid) vaccine, a plasmid and a preparation method thereof, and aims to provide the avian coronavirus mRNA vaccine which is high in immunogenicity and good in safety, the avian coronavirus mRNA vaccine is formed by wrapping mRNA with nucleotide lipid nanoparticles, and the mRNA is mRNA-N with a nucleotide sequence as shown in SEQ ID NO.1; or the nucleotide sequence of the mRNA-N-Mosaic is shown as SEQ ID NO.2. The invention belongs to the technical field of vaccines.

The present disclosure relates to methods, compositions, and systems for detecting whether a subject exposed to a coronavirus has developed a neutralizing antibody response. Also disclosed are methods for determining whether a patient infected by a coronavirus is likely to respond to treatment with an antibody preparation. Also disclosed are methods for detecting the level of neutralizing antibody response in a sample of serum from a subject exposed to a coronavirus or to a coronavirus vaccine.

This invention belongs to the field of biomedical technology, specifically relating to an antigenic epitope peptide combination for a broad-spectrum novel coronavirus vaccine and its application. The antigenic epitope peptide combination of this invention includes a combination of viral spike protein Epi-I antigenic epitope peptides, a combination of viral spike protein Epi-II antigenic epitope peptides, and a combination of viral spike protein Epi-III antigenic epitope peptides. These antigenic epitope peptide combinations are obtained by screening spike protein epitopes from three broad-spectrum neutralizing antibodies against SARS-CoV-2, and can induce a broad-spectrum neutralizing antibody response in the host, used for the preparation of a broad-spectrum novel coronavirus vaccine. Using the antigenic epitope peptide combination of this invention, an antigenic epitope fusion protein L9 was obtained and prepared into a vaccine. The results of the examples show that the L9 vaccine has a better neutralizing effect against SARS-CoV-2 variants than the control group of the Wuhan strain of SARS-CoV-2 spike protein RBD, exhibiting good cross-neutralization.

The application discloses a SARS-CoV-2 epitope type vaccine multi-epitope combination and application, and belongs to the technical field of coronavirus vaccine research and development.The first aspect of the application relates to a fusion protein, which comprises in sequence: (a) a SARS-CoV-2 spike protein receptor binding domain or a functional fragment thereof; (b) a T cell epitope domain, comprising: a CTL epitope cluster, the CTL epitope cluster comprising at least one CD8+ T cell epitope polypeptide selected from SEQ ID NO: 1-15; and (c) an immunoglobulin Fc domain.The application adopts a tandem strategy of immunodominant epitopes + conserved epitopes, predicts high-affinity T cell epitopes by computational biology methods, evaluates the HLA restriction in different populations, introduces a flexible linker peptide for optimization design, evaluates the immune effect difference of different combinations through in vitro and animal models, analyzes the synergistic or competitive relationship between epitopes, and optimizes the vaccine design.Through systematic comparison of the immunological effect difference of different epitope combinations and the adaptability to various vaccine platforms, the application establishes an optimized safe, efficient, broad-spectrum and long-acting multi-epitope vaccine design strategy, and has significant application value and important transformation value.

A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and / or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N / mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.

The present disclosure relates to coronavirus vaccines and methods for use thereof.

The present disclosure relates to methods, compositions, and systems for detecting whether a subject exposed to a coronavirus has developed a neutralizing antibody response. Also disclosed are methods for determining whether a patient infected by a coronavirus is likely to respond to treatment with an antibody preparation. Also disclosed are methods for detecting the level of neutralizing antibody response in a sample of serum from a subject exposed to a coronavirus or to a coronavirus vaccine.

Disclosed are synthetic modified vaccinia Ankara (MVA)-based vaccines for preventing or treating coronavirus infections, and methods for producing the vaccines. Specifically, the disclosure provides vaccine compositions for preventing or treating coronavirus infections, comprising (i) a synthetic DNA fragment or two or more synthetic DNA fragments comprising the entire genome of MVA, and (ii) one or more DNA sequences encoding one or more coronavirus antigens, subunits thereof, or fragments thereof, inserted into one or more insertion sites of the MVA. TIFF2023526073000042.tif47150

The present application relates to the field of CpG content detection method, particularly to a method for detecting CpG content in a double-adjuvant recombinant novel coronavirus vaccine (Pichia pastoris), comprising the following steps: S1: taking 1ml of the novel coronavirus vaccine (Pichia pastoris) test sample and loading it into a 10ml EP tube, adding 1ml of 3% sodium hydroxide solution, ensuring that the seal is intact, heating to clarity in a boiling water bath for 15 minutes, shaking well, precisely taking 100ul of the mixed solution and loading it into a 10ml EP tube, adding 4.9ml of water, shaking well, and taking it as the test sample solution, a total dilution of 100 times, the present application has the following beneficial effects: low cost, saving test solution, only using sodium hydroxide; after treatment, there is no electrostatic adsorption and coordination reaction in the test sample, and the CpG content can be accurately determined.

The present disclosure relates generally to novel recombinant coronavirus-based fusion proteins (“RBDs-IgG Fc protein” and “RBDs protein”) and vaccine compositions using the same, in which the fusion proteins comprise tandemly arranged coronaviruses receptor binding domains (RBDs). The present disclosure further provides methods and kits for immunizing a subject using the compositions.

The present invention relates to: a conjugate in which a receptor-binding domain (RBD) of coronavirus and a hepatitis B surface antigen (HBsAg) are linked; virus-like particles including the conjugate; and a coronavirus vaccine composition containing the conjugate and / or virus-like particles.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Disclosed are synthetic MVA-based vaccines for preventing or treating coronavirus infections and methods of producing the vaccines.

The application discloses a novel coronavirus vaccine based on controllable secretion expression of attenuated salmonella, a preparation method and application thereof, and is used for preventing the novel coronavirus. The application constructs controllable, stable and secretory expression plasmids of different antigen domain proteins of the novel coronavirus and attenuated salmonella expression strains of the different antigen domain proteins; a plurality of attenuated salmonella antigen presentation strains which can controllably and secretively express in antigen presenting cells are mixed, and through an oral route, the plurality of different antigen proteins can be efficiently secretively expressed in the antigen presenting cells by means of the unique secretion system of the attenuated salmonella after administration. The secretively expressed antigenic proteins can be effectively processed and presented by the antigen presenting cells, and finally the immune system is activated / regulated, higher titer antibodies are generated, and the vaccine plays a role.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses against various SARS-CoV-2 variants of concern.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus Infection, preferably a Coronavirus infection.

The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and / or diagnostic methods, and related kits.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

The application discloses a recombinant protein and vaccine of a novel Middle East respiratory syndrome coronavirus, wherein the amino acid sequence of the recombinant protein comprises a sequence of two, three or four 367-602 amino acid fragments of a S protein RBD region of the Middle East respiratory syndrome coronavirus connected in series, or a sequence with more than 95% identity with the sequence of the amino acid fragments and having the same or similar biological activity. The recombinant Middle East respiratory syndrome (MERS) coronavirus vaccine prepared by mixing the target antigen with an adjuvant can produce a high-titer antibody level after immunizing an organism, and can be used for treating and / or preventing Middle East respiratory syndrome (MERS) coronavirus infection and / or disease.

The invention provides a T cell immunodominance epitope peptide of an SARS-CoV-2 nucleocapsid protein mutation site and application of the T cell immunodominance epitope peptide, and belongs to the technical field of biological medicine. According to the invention, a group of dominant epitope peptide compounds capable of specifically targeting mutation sites and activating T cell response are developed by screening and identifying dominant epitopes aiming at N protein of an Omicron mutant strain JN.1 substrain. The epitope peptide can induce an organism to generate an effective specific T cell immune response aiming at a current main epidemic Omicron pedigree JN.1 substrain mutation site, so that the cellular immunocompetence of the organism is enhanced. A novel coronavirus vaccine, a medicine or an antigen detection kit developed based on the epitope peptide compound can provide possibility for effectively removing virus infected cells, reducing continuous existence of viruses in vivo and identifying new coronavirus infection, so that SARS-CoV-2 breakthrough infection is diagnosed and prevented in an early stage, and the long-term health burden of a patient is relieved.

The application relates to the technical field of antibodies, in particular to a novel coronavirus Omicron mutant specific antibody and application thereof. The application provides an antibody specifically combined with the novel coronavirus Omicron mutant, the antibody can be used as a specific antibody for antigen detection of the Omicron mutant, is used for identification of a novel coronavirus vaccine designed for the Omicron mutant, and is used for quantitative detection of the content of Spike RBD protein expressed by the vaccine, or is used for quality control of a novel coronavirus vaccine and immunogenicity detection of clinical and preclinical research, or is used as a quality control antibody for detection of protective antibodies in serum after vaccination.

This invention discloses a novel coronavirus T-cell antigenic epitope peptide and its application in vaccine preparation. The amino acid sequence of the novel coronavirus T-cell antigenic epitope peptide is shown in any one of SEQ ID NO: 1 to 9. A pMHC complex monomer was prepared using this peptide, and a pMHC complex polymer was further prepared. These can be used to detect antigen-specific T cells in the peripheral blood of novel coronavirus vaccine recipients and recovered patients, and for in vitro T-cell activation experiments. These novel coronavirus T-cell antigenic epitope peptides can be used in the preparation of universal vaccines against various novel coronavirus mutant strains, novel coronavirus-related immune detection, and the development of broad-spectrum therapeutic drugs, and are worthy of in-depth research and widespread promotion.

The invention discloses a polymer protein nanoparticle and application thereof in preparation of a novel coronavirus broad-spectrum vaccine, and the polymer protein nanoparticle is prepared by forming a pentamer compound FP-HR5 fusion protein by using heptapeptide repeat regions HR1 and HR2 and a fusion peptide FP on a coronavirus S protein, and on the basis, assembling with Ferritin to obtain the polymer protein nanoparticle. And preparing the novel coronavirus antigen polymer compound FP-HR5-NP protein nanoparticles. The novel coronavirus universal nanoparticle vaccine which can be inoculated through injection or a respiratory system and has a good immune protection effect is prepared by taking the coronavirus as an immunogen. The obtained novel coronavirus vaccine is good in immune protection effect, mucosal immunity can be remarkably activated after a respiratory system is inoculated, infection of novel coronaviruses of different mutant strains can be avoided after the respiratory system is inoculated, the preparation method is simple, the protein expression and purification technical route is mature, safety is high, and the novel coronavirus vaccine can be rapidly applied to clinical tests.